G. Cremonesi et al. / Tetrahedron 70 (2014) 2054e2058
2057
added, and the mixture was extracted with ethyl acetate (3ꢂ10 mL).
The organic phase was separated and dried with Na2SO4, and the
solvent was evaporated in vacuo. Compounds 3, 4 were purified by
means of flash chromatography (SiO2, CH2Cl2/hexane¼40/60 for 3a
(Rf 0.2) and 4a (Rf 0.4); CH2Cl2/ethyl acetate¼95/5 for 3d (Rf 0.4) and
4d (Rf 0.5), 3e (Rf 0.5) and 4e (Rf 0.6); CH2Cl2/ethyl acetate¼98/2 for
4f (Rf 0.6)).
system, J¼12.1, 25.3, 2H, CH2); 5.55 (dd, J¼3.3, 9.5, 1H, H-10); 5.38
(d, J¼9.5, 1H, NH); 7.25e7.41 (m, 10H, Ph). MS-ESIþ (m/z): 424
[MþH]þ.
4.2.6. Benzyl (S)-[(2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazin-2-yl](phenyl)methylcarbamate
(4e). Amorphous
solid (275.0 mg, 65%). [
a
]
20 þ19.8 (c 0.3, CHCl3). 1H NMR:
d 0.59, 0.91
D
(2d, J¼6.7, 6H, CH(CH3)2); 2.11 (m, 1H, CH(CH3)2); 3.24 (t, J¼3.3, 1H,
H-5); 3.68 (s, 3H, OCH3); 3.74 (s, 3H, OCH3); 4.42 (t, J¼3.6, 1H, H-2);
5.1 (AB system, J¼12.1, 25.3, 2H, CH2); 5.38 (dd, J¼3.6, 9.2, 1H, H-10);
4.2.1. N-{(R)-[(2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-
2-yl](phenyl)methyl}-N-phenylamine (3a). Colourless solid (138.7
mg, 38%); mp 89e91 ꢁC (hexane). [
a]
D
20 þ92.3 (c 1.9, CHCl3). 1H NMR:
6.31 (broad d, J¼9.2,1H, NH); 7.05e7.45 (m,10H, Ph).13C NMR:
d 16.7,
d
0.66, 0.98 (2d, J¼6.8, 6H, CH(CH3)2); 2.18 (m, 1H, CH(CH3)2); 3.59 (t,
19.1 (CH(CH3)2); 31.6 (CH(CH3)2); 52.3, 52.8 (3- and 6-OCH3); 56.2 (C-
10); 59.8, 60.5 (C-2 and C-5); 67.1 (CH2); 127.6e129.9 (Ph); 136.7 (Ph);
138.1 (Ph); 155.8 (CO); 160.2, 165.5 (C-3 and C-6). Anal. Calcd for
J¼3.5, 1H, H-5); 3.71 (s, 3H, OCH3); 3.73 (s, 3H, OCH3); 4.35 (t, J¼3.5,
1H, H-2); 4.55 (broad s, 1H, NH); 5.01 (d, J¼2.2, 1H, H-10); 6.54e6.66
(m, 3H, Ph); 7.05e7.35 (m, 7H, Ph). 13C NMR:
d
16.7, 19.0 (CH(CH3)2);
C24H29N3O4: C, 68.06; H, 6.90; N, 9.92. Found: C, 67.89; H 6.85; N,
31.7 (CH(CH3)2); 52.6 (3- and 6-OCH3); 59.1 (C-10); 60.6, 60.7 (C-2
and C-5); 113.8e129.0 (Ph); 140.4, 146.9 (Ph); 161.3, 165.9 (C-3 and C-
6). IR (Nujol): 3453 (vNH, NH), 1693 (vC]N, C]N). Anal. Calcd for
9.78. MS-ESIþ (m/z): 424 [MþH]þ.
4.2.7. N-[(R)-[(2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-
C
22H27N3O2: C, 72.30; H, 7.45; N, 11.50. Found: C, 72.25; H 7.36; N,
2-yl](phenyl)methyl]benzenesulfonamide (4f). Colourless solid (184.5
20
11.33. MS-ESIþ (m/z): 366 [MþH]þ.
mg, 43%); mp 180e181 ꢁC (ethanol). [
a]
D
þ79.9 (c 0.4, CHCl3). 1H
NMR:
d
0.60, 0.90 (2d, J¼6.9, 6H, CH(CH3)2); 2.10 (m, 1H, CH(CH3)2);
4.2.2. N-{(S)-[(2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-
2-yl](phenyl)methyl}-N-phenylamine (4a). Amorphous solid (124.1
mg, 34%). [
3.28 (t, J¼3.5,1H, H-5); 3.65 (s, 3H, OCH3); 3.77 (s, 3H, OCH3); 4.36 (t,
J¼3.9, 1H, H-2); 5.12 (dd, J¼3.9, 9.5, 1H, H-10); 6.21 (broad d, J¼9.5,
1H, NH); 6.91e7.44 (m, 8H, Ph); 7.72 (d, J¼7.6, 2H, Ph). 13C NMR:
a]
D
20 þ61.8 (c 1.0, CHCl3). 1H NMR:
d
0.60, 0.91 (2d, J¼6.9,
6H, CH(CH3)2); 2.11 (m,1H, CH(CH3)2); 3.10 (t, J¼3.5,1H, H-5); 3.73 (s,
3H, OCH3); 3.78 (s, 3H, OCH3); 4.56 (t, J¼3.5, 1H, H-2); 5.04 (d, J¼3.7,
1H, H-10); 6.58e6.64 (m, 3H, Ph); 7.06e7.25 (m, 7H, Ph); 7.55 (broad
d 16.4, 18.8 (CH(CH3)2); 31.5 (CH(CH3)2); 52.0, 52.8 (3- and 6-OCH3);
58.0 (C-10); 59.8, 60.4 (C-2 and C-5); 126.8e132.0 (Ph); 135.9 (Ph);
140.9 (Ph); 159.5,165.5 (C-3 and C-6). Anal. Calcd for C22H27N3O4S: C,
61.52; H, 6.34; N, 9.78. Found: C, 61.47; H 6.27; N, 9.64. MS-ESIþ (m/
z): 430 [MþH]þ.
s, 1H, NH). 13C NMR:
d 16.7, 19.4 (CH(CH3)2); 31.2 (CH(CH3)2); 52.1,
52.5 (3- and 6-OCH3); 58.4 (C-10); 59.8, 60.0 (C-2 and C-5);
113.5e131.3 (Ph); 138.2, 146.7 (Ph); 160.3, 164.9 (C-3 and C-6). IR
(Nujol): 3428 (vNH, NH), 1696 (vC]N, C]N). Anal. Calcd for
4.3. General procedure for the hydrolysis of adducts 3, 4
C
22H27N3O2: C, 72.30; H, 7.45; N, 11.50. Found: C, 72.20; H 7.33; N,
11.42. MS-ESIþ (m/z): 366 [MþH]þ.
Aqueous HCl 0.1 N (4.5 mL, 3 equiv) was added to a solution of
adduct 3, 4 (0.15 mmol,1 equiv) in CH3CN (1.5 mL). The mixture was
stirred for 54e72 h at room temperature and then extracted with
diethyl ether in order to remove non-basic organic compounds. It
was then treated with 25% ammonia solution under stirring until
pH¼8e10, and extracted with AcOEt (4ꢂ5 mL). The combined or-
ganic layers were dried with Na2SO4, and the solvent was removed
in vacuo. Compounds 6d and 7 were separated by means of flash
chromatography (SiO2, toluene/ethanol¼2/1, developer: ninhy-
drin). Compounds 5d, 6e and f were purified by means of column
chromatography (SiO2, toluene/ethanol¼2/1 for 5d, AcOEt/meth-
anol¼95/5 for 6e and AcOEt/methanol¼98/2 for 6f, developer:
ninhydrin).
4.2.3. tert-Butyl (R)-[(2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazin-2-yl](phenyl)methylcarbamate
(3d). Amorphous
20
solid (105.0 mg, 27%). [
a]
þ20.5 (c 0.4, CHCl3). 1H NMR:
d 0.63,
D
0.96 (2d, J¼6.8, 6H, CH(CH3)2); 1.41 (s, 9H, C(CH3)3); 2.17 (m, 1H,
CH(CH3)2); 3.64 (t, J¼3.3, 1H, H-5); 3.69 (s, 3H, OCH3); 3.75 (s, 3H,
OCH3); 4.29 (broad s, 1H, H-2); 5.22e5.35 (broad m, 2H, H-10, NH);
7.24e7.53 (m, 5H, Ph). 13C NMR:
d 16.9, 19.2 (CH(CH3)2); 28.5
(C(CH3)3); 31.9 (CH(CH3)2); 52.9 (3- and 6-OCH3); 56.4 (C-10); 60.5,
60.9 (C-2 and C-5); 79.7 (C(CH3)3); 127.3e130.0 (Ph); 140.3 (Ph);
155.1 (CO); 161.5, 163.2 (C-3 and C-6). Anal. Calcd for C21H31N3O4: C,
64.76; H, 8.02; N, 10.79. Found: C, 64.55; H 7.87; N, 10.65. MS-ESIþ
(m/z): 390 [MþH]þ.
4.3.1. Methyl (2S,3R)-2-amino-3-[(tert-butoxycarbonyl)amino]-3-
20
4.2.4. tert-Butyl (S)-[(2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
phenylpropanoate (5d). Amorphous solid (26.0 mg, 59%). [a]
D
20
dihydropyrazin-2-yl](phenyl)methylcarbamate
(4d). Amorphous
þ22.5 (c 0.2, CHCl3). Lit.21 for (2R,3S) derivate: [
a
]
D
ꢀ23.7 (c 1,
20
solid (147.8 mg, 38%). [
a
]
þ20.8 (c 0.5, CHCl3). 1H NMR:
d
0.58,
CHCl3). 1H NMR:
d 1.40 (s, 9H, C(CH3)3); 2.55 (broad s, 2H, NH2);
D
0.89 (2d, J¼7.0, 6H, CH(CH3)2); 1.45 (s, 9H, C(CH3)3); 2.11 (m,
1H, CH(CH3)2); 3.19 (t, J¼3.3, 1H, H-5); 3.67 (s, 3H, OCH3); 3.76 (s,
3H, OCH3); 4.39 (t, J¼3.6, 1H, H-2); 5.32 (dd, J¼3.6, 8.8, 1H, H-10);
6.00 (broad d, J¼8.8, 1H, NH); 7.05e7.37 (m, 5H, Ph). 13C NMR:
3.76 (s, 3H, OCH3); 3.92 (d, J¼2.9, 1H, H-3); 5.23 (m, 1H, H-2); 5.81
(broad d, J¼8.8, 1H, NH); 7.22e7.35 (m, 5H, Ph). 13C NMR:
d 28.5
(C(CH3)3); 52.7 (OCH3); 56.6 (C-3); 58.7 (C-2); 79.9 (C(CH3)3);
126.6e139.9 (Ph); 155.3 (CO); 173.0 (CO). IR (Nujol): 3415 (vNH
,
d
16.6, 19.1 (CH(CH3)2); 28.5 (C(CH3)3); 31.6 (CH(CH3)2); 52.3, 52.8
NH2), 1734 (vC]O, C]O), 1692 (vC]O, C]O). Anal. Calcd for
(3- and 6-OCH3); 55.8 (C-10); 60.0, 60.4 (C-2 and C-5); 79.7
(C(CH3)3); 127.5e127.9 (Ph); 138.4 (Ph); 155.3 (CO); 160.4, 165.3
(C-3 and C-6). Anal. Calcd for C21H31N3O4: C, 64.76; H, 8.02; N,
10.79. Found: C, 64.61; H 7.92; N, 10.70. MS-ESIþ (m/z): 390
[MþH]þ.
C15H22N2O4: C, 61.21; H, 7.53; N, 9.52. Found: C, 61.05; H 7.48; N,
9.38. MS-ESIþ (m/z): 295 [MþH]þ.
4.3.2. Methyl (2S,3S)-2-amino-3-[(tert-butoxycarbonyl)amino]-3-
20
phenylpropanoate (6d). Amorphous solid (18.5 mg, 42%). [a]
D
þ24.9 (c 0.4, CHCl3). Lit.21
[
a
]
D
20 þ26.7 (c 1, CHCl3). 1H NMR:
d 1.40 (s,
4.2.5. Benzyl (R)-[(2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
9H, C(CH3)3); 1.55 (broad s, 2H, NH2); 3.68 (s, 3H, OCH3); 3.85 (d,
dihydropyrazin-2-yl](phenyl)methylcarbamate
(3e). Amorphous
J¼4.3, 1H, H-3); 5.11 (broad s, 1H, H-2); 5.86 (broad d, J¼7.2, 1H,
solid (42.3 mg, 10%). 1H NMR:
d
0.63, 0.96 (2d, J¼6.9, 6H,
NH); 7.20e7.40 (m, 5H, Ph). 13C NMR:
d 28.6 (C(CH3)3); 52.3 (OCH3);
CH(CH3)2); 2.13 (m, 1H, CH(CH3)2); 3.61 (t, J¼3.7, 1H, H-5); 3.68 (s,
3H, OCH3); 3.74 (s, 3H, OCH3); 4.29 (t, J¼3.3, 1H, H-2); 5.1 (AB
56.4 (C-3); 58.8 (C-2); 80.0 (C(CH3)3); 126.9e138.0 (Ph); 155.4 (CO);
173.8 (CO). IR (Nujol): 3376 (vNH, NH2), 1726 (vC]O, C]O), 1698